EF Hutton Assumes Lantern Pharma at Buy, Maintains Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Michael King assumes Lantern Pharma (NASDAQ:LTRN) with a Buy rating and maintains a price target of $11.
May 25, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantern Pharma receives a Buy rating from EF Hutton analyst Michael King, with a maintained price target of $11.
The Buy rating from EF Hutton analyst Michael King indicates a positive outlook for Lantern Pharma's stock. The maintained price target of $11 suggests that the analyst believes the stock has potential for growth in the short term. This news is directly related to LTRN and is important for investors as it provides a professional opinion on the stock's potential performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100